Neeraj Agarwal: Unacceptably low rates of NGS testing in metastatic Prostate Cancer
Neeraj Agarwal shared a post on X about a recent paper by Chadi Hage Chehade et al. published in JAMA Network Open, commenting:
“Just in JAMA Network Open.
Unacceptably low rates of NGS testing in metastatic Prostate Cancer and bladder cancer in real world patients (worse in Black and Hispanic patients), Flatiron Health.
Proud of our postdoc, Chadi, Yeonjung, George and the team for terrific mentoring by Umang Swami, GU Cancer Research Program.”
“Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers”
Authors: Chadi Hage Chehade, Yeonjung Jo, Georges Gebrael, Nishita Tripathi, Nicolas Sayegh, Beverly Chigarira, Vinay Mathew Thomas, Gliceida Galarza Fortuna, Arshit Narang, Patrick Campbell, Sumati Gupta, Benjamin L. Maughan, Soumyajit Roy, Neeraj Agarwal, Umang Swami.
Source: Neeraj Agarwal/X
Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.
Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.
